Skip to main content
SpringerLink
Log in

Management of Nasopharyngeal Carcinoma

  • Chapter
  • First Online:
Head and Neck Cancer

  • 2516 Accesses

Abstract

Nasopharyngeal carcinoma (NPC) is a distinctly radiosensitive and chemosensitive tumor. Best quality radiotherapy is demanded to build up the complex concave high-dose zone for this critical location. Intensity-modulated (IMRT) technique is advocated, image guidance to ensure setup precision and adaptive re-planning if major deviations from intended dose distribution occur during the treatment course are useful improvements if resources allow. Stringent dose constraint to organs at risk should be attempted to minimize late toxicities. Addition of cisplatin-based concurrent-adjuvant chemotherapy is recommended for patients with stages III–IVB and high-risk stage IIB diseases. More contemporary series using IMRT together with extensive use of chemotherapy and acceleration reported very encouraging early results with locoregional control in excess of 90% at 2–4 years; the key remaining problem is distant failure. Further improvement of efficacy by changing chemotherapy sequence to induction-concurrent is being explored.The plasma level of Epstein–Barr Viral Deoxyribonucleic Acid is an additional tool for nonkeratinizing carcinoma for prognostication and monitoring disease progress. Integrated fluorodeoxyglucose positron emission tomography and computed tomography is useful for excluding distant metastases and posttreatment persistent/recurrent disease. Early detection of failure is critical for increasing the chance of salvage; aggressive treatment should be attempted as far as possible, long survival can be achieved for patients with limited failure or metastasis. Different salvage methods and reported results are summarized.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Liao XB, Mao YP, Liu LZ, et al. How does magnetic resonance imaging influence staging according to AJCC Staging System for nasopharyngeal carcinoma compared with computed tomography? Int J Radiat Oncol Biol Phys. 2008;72:1368–77.

    PubMed  Google Scholar 

  2. Chua ML, Ong SC, Wee JT, et al. Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. Head Neck. 2009;31:346–54.

    PubMed  Google Scholar 

  3. Ng SH, Chan SC, Yen TC, et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging. 2009;36:12–22.

    PubMed  Google Scholar 

  4. Edge SB, Byrd DR, Compton CA, editors. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.

    Google Scholar 

  5. Sobin L. International Union Against Cancer (UICC): TNM classification of malignant tumors. 7th ed. Oxford UK, Wiley-Blackwell; 2009.

    Google Scholar 

  6. Som PM, Curtin HD. Head and neck imaging. 3rd ed. St Louis: Mosby; 1999.

    Google Scholar 

  7. Lee AW, Au JS, Teo PM, et al. Staging of nasopharyngeal carcinoma: suggestions for improving the current UICC/AJCC Staging System. Clin Oncol. 2004;16:269–76.

    CAS  Google Scholar 

  8. Low JS, Heng DM, Wee JT. The question of T2a and N3a in the UICC/AJCC (1997) staging system for nasopharyngeal carcinoma. Clin Oncol. 2004;16:581–3.

    CAS  Google Scholar 

  9. Liu MZ, Tang LL, Zong JF, et al. Evaluation of the sixth edition of AJCC Staging System for nasopharyngeal carcinoma and proposed improvement. Int J Rad Oncol Biol Phys. 2008;70:1115–23.

    Google Scholar 

  10. Mao YP, Xie FY, Liu LZ, et al. Re-Evaluation of 6th Edition of AJCC Staging System for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73:1326–34.

    PubMed  Google Scholar 

  11. Tang LL, Li L, Mao Y, et al. Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma detected by magnetic resonance imaging. Cancer. 2008;113:347–54.

    PubMed  Google Scholar 

  12. Leung SF, Chan AT, Zee B, et al. Pretherapy quantitative mea­surement of circulating Epstein-Barr virus DNA is predictive of ­posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer. 2003;98:288–91.

    PubMed  Google Scholar 

  13. Leung SF, Zee B, Ma B, et al. Plasma Epstein-Barr Viral Deoxyribonucleic Acid quantitation complements tumor node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006;24:5414–8.

    PubMed  CAS  Google Scholar 

  14. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461–70.

    PubMed  CAS  Google Scholar 

  15. Twu CW, Wang WY, Liang WM, et al. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;67:130–7.

    PubMed  CAS  Google Scholar 

  16. Le QT, Jones CD, Yau TK, et al. A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res. 2005;11:5700–7.

    PubMed  CAS  Google Scholar 

  17. Mesic JB, Fletcher GH, Goepfert H. Megavoltage irradiation of epithelial tumors of the nasopharynx. Int J Radiat Oncol Biol Phys. 1981;7:447–53.

    PubMed  CAS  Google Scholar 

  18. Perez CA, Devineni VR, Marcial-Vega V, et al. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys. 1992;23:271–80.

    PubMed  CAS  Google Scholar 

  19. Teo PML, Leung SF, Tung SY. Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: A study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG). Radiother Oncol. 2006;79:27–33.

    PubMed  Google Scholar 

  20. Lee AW, Chan DK, Fowler JF, et al. Effect of time, dose and fractionation on local control of nasopharyngeal carcinoma. Radiother Oncol. 1995;36:24–31.

    PubMed  CAS  Google Scholar 

  21. Lee AW, Foo W, Chappell R, et al. Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1998;40:35–42.

    PubMed  CAS  Google Scholar 

  22. Lee AW, Kwong DL, Leung SF, et al. Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time. Int J Radiat Oncol Biol Phys. 2002;53:75–85.

    PubMed  Google Scholar 

  23. Leung TW, Wong VY, Sze WK, et al. High dose-rate brachytherapy boost for early T stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2008;70:361–7.

    PubMed  Google Scholar 

  24. Hara W, Loo BW, Goffinet DR, et al. Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2008;71:393–400.

    PubMed  Google Scholar 

  25. Vikram B, Mishra UB, Strong EW, et al. Patterns of failure in carcinoma of the nasopharynx: I Failure at the primary site. Int J Radiat Oncol Biol Phys. 1985;11:1455–9.

    PubMed  CAS  Google Scholar 

  26. Kwong DL, Sham JS, Chua DT, et al. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1997;39:703–10.

    PubMed  CAS  Google Scholar 

  27. Teo ML, Leung SF, Chan TK, et al. Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. Int J Radiat Oncol Biol Phys. 2000;48:1311–22.

    PubMed  CAS  Google Scholar 

  28. Daoud J, Toumi N, Siala W, et al. Results of a prospective randomised trial comparing conventional radiotherapy to split course bifractionated radiation therapy in patients with nasopharyngeal carcinoma. Radiother Oncol. 2007;85:17–23.

    PubMed  Google Scholar 

  29. Lee AW, Tung SY, Chan AT, et al. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:142–51.

    PubMed  Google Scholar 

  30. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology. 2004;233:93–100.

    PubMed  Google Scholar 

  31. Schinagl DA, Vogel WV, Hoffmann AL, et al. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:1282–9.

    PubMed  CAS  Google Scholar 

  32. Xia P, Fu KK, Wong GW, et al. Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2000;48:329–937.

    PubMed  CAS  Google Scholar 

  33. Cheng JC, Chao KS, Low D. Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer. 2001;96:126–32.

    PubMed  CAS  Google Scholar 

  34. Hunt MA, Zelefsky MJ, Wolden S, et al. Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys. 2001;49:623–32.

    PubMed  CAS  Google Scholar 

  35. Kam MK, Chau RM, Suen J, et al. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys. 2003;56:145–57.

    PubMed  Google Scholar 

  36. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53:12–22.

    PubMed  Google Scholar 

  37. Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225. J Clin Oncol. 2009;27:3684–90.

    PubMed  Google Scholar 

  38. Wolden SL, Chen WC, Pfister DG, et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: Update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys. 2006;64:57–62.

    PubMed  Google Scholar 

  39. Pow HN, Kwong LW, McMillan S, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006;66:981–91.

    PubMed  Google Scholar 

  40. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25:4873–9.

    PubMed  Google Scholar 

  41. Amdur RJ, Li JG, Liu C, et al. Unnecessary laryngeal irradiation in the IMRT era. Head Neck. 2004;26:257–64.

    PubMed  Google Scholar 

  42. Parliament M, Alidrisi M, Munroe M, et al. Implications of radiation dosimetry of the mandible in patients with carcinomas of the oral cavity and nasopharynx treated with intensity modulated radiation therapy. Int J Oral Maxillofac Surg. 2005;34:114–21.

    PubMed  CAS  Google Scholar 

  43. Fua TF, Corry J, Milner AD, et al. Intensity-modulated radiotherapy for nasopharyngeal carcinoma: clinical correlation of dose to the pharyngo-esophageal axis and dysphagia. Int J Radiat Oncol Biol Phys. 2007;67:976–81.

    PubMed  Google Scholar 

  44. Hall WH, Guiou M, Lee NY, et al. Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2008;72:1362–7.

    PubMed  Google Scholar 

  45. Vitolo V, Millender LE, Quivey JM, et al. Assessment of carotid artery dose in the treatment of nasopharyngeal cancer with IMRT versus conventional radiotherapy. Radiother Oncol. 2009;90:213–20.

    PubMed  Google Scholar 

  46. Wang J, Bai S, Chen N, et al. The clinical feasibility and effect of online cone beam computer tomography-guided intensity-modulated radiotherapy for nasopharyngeal cancer. Radiother Oncol. 2009;90:221–7.

    PubMed  Google Scholar 

  47. Barker Jr JL, Garden AS, Ang KK, et al. Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys. 2004;59:960–70.

    PubMed  Google Scholar 

  48. Hansen EK, Bucci MK, Quivey JM, et al. Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006;64:355–62.

    PubMed  Google Scholar 

  49. Fiorino C, Dell’Oca I, Pierelli A, et al. Simultaneous accelerated boost (SIB) for nasopharynx cancer with helical tomotherapy. Strahlentherapie und Onkologie. 2007;183:497–505.

    PubMed  Google Scholar 

  50. Lee TF, Fang FM, Chao PJ, et al. Dosimetric comparisons of helical tomotherapy and step-and-shoot intensity-modulated radiotherapy in nasopharyngeal carcinoma. Radiother Oncol. 2008;89:89–96.

    PubMed  Google Scholar 

  51. Taheri-Kadkhoda Z, Björk-Eriksson T, Nill S et al. Intensity-modulated radiotherapy of nasopharyngeal carcinoma: a comparative treatment planning study of photons and protons. Rad Oncol. 2008;3:4 (http://www.ro-journal.com/content/3/1/4)

  52. Widesott L, Pierelli A, Fiorino C, et al. Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. Int J Radiat Oncol Biol Phys. 2008;72:589–96.

    PubMed  Google Scholar 

  53. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64:47–56.

    PubMed  CAS  Google Scholar 

  54. Chan AT, Teo PM, Leung TW, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1995;33:569–77.

    PubMed  CAS  Google Scholar 

  55. Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer. 1998;83:2270–83.

    PubMed  CAS  Google Scholar 

  56. Cvitkovic E, Eschwege F, Rahal M, et al. Preliminary results of trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (>N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression free survival. Int J Radiat Oncol Biol Phys. 1996;35:463–9.

    CAS  Google Scholar 

  57. Hareyama M, Sakata K, Shirato H, et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer. 2002;94:2217–23.

    PubMed  CAS  Google Scholar 

  58. Chi KH, Chang YC, Guo WY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2002;52:1238–44.

    PubMed  CAS  Google Scholar 

  59. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310–7.

    PubMed  CAS  Google Scholar 

  60. Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol. 2004;22:2643–53.

    PubMed  CAS  Google Scholar 

  61. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97:536–9.

    PubMed  CAS  Google Scholar 

  62. Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005;23:6966–75.

    PubMed  CAS  Google Scholar 

  63. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer Stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23:6730–8.

    PubMed  CAS  Google Scholar 

  64. Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int J Radiat Oncol Biol Phys. 2008;71:1356–64.

    PubMed  Google Scholar 

  65. Lin JC, Jan JS, Hsu CY, et al. Concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631–7.

    PubMed  Google Scholar 

  66. Lin JC, Liang WM, Jan JS, et al. Another way to estimate outcome of advanced nasopharyngeal carcinoma – is concurrent chemoradiotherapy adequate. Int J Radiat Oncol Biol Phys. 2004;60:156–64.

    PubMed  Google Scholar 

  67. Zhang L, Zhao C, Peng PJ, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol. 2005;23:8461–8.

    PubMed  CAS  Google Scholar 

  68. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer. 2007;43:1399–406.

    PubMed  CAS  Google Scholar 

  69. Yau TK, Lee AW, Wong DH, et al. Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: Impact of chemotherapy schemes. Int J Radiat Oncol Biol Phys. 2006;66:1004–10.

    PubMed  CAS  Google Scholar 

  70. Cheng SH, Tsai YC, Yen KL, et al. Prognostic significance of parapharyngeal space venous plexus and marrow involvement: Potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:456–65.

    PubMed  Google Scholar 

  71. Rischin D, Corry J, Smith J, et al. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol. 2002;20:1845–52.

    PubMed  CAS  Google Scholar 

  72. Lee AW, Yau TK, Wong HM, et al. Treatment of stage IV(A-B) Nasopharyngeal Carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. Int J Radiat Oncol Biol Phys. 2005;63:1331–8.

    PubMed  Google Scholar 

  73. Yau TK, Lee AW, Wong HM, et al. Induction chemotherapy with Cisplatin and Gemcitabine followed by accelerated radiotherapy and concurrent Cisplatin in patients with stage IV(A-B) Nasopharyngeal Carcinoma. Head Neck. 2006;28:880–7.

    PubMed  Google Scholar 

  74. Al-Sarraf M, LeBlanc M, Giri PGS et al. Chemo-radiotherapy (CT-RT) vs. radiotherapy (RT) in patients (PTS) with advanced nasopharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) Phase III Study: progress report. J Clin Oncol. 1998b;17:385a [abstract]

    Google Scholar 

  75. Lee AW, Lau KY, Hung WM, et al. Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiother Oncol. 2008;87:204–10.

    PubMed  CAS  Google Scholar 

  76. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of cisplatin-radiotherapy with and without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27:242–9.

    PubMed  CAS  Google Scholar 

  77. Liu T, Xu W, Yan WL, et al. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol. 2007;85:327–35.

    PubMed  Google Scholar 

  78. Chan AT, Lo DY, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002;94:1614–9.

    PubMed  CAS  Google Scholar 

  79. Chan AT, Ma BY, Lo YM, et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr Virus DNA. J Clin Oncol. 2004;22:3053–60.

    PubMed  CAS  Google Scholar 

  80. Lin JC, Wang WY, Liang WM, et al. Long-term prognostic effects of plasma Epstein-Barr Virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients     receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1342–8.

    PubMed  CAS  Google Scholar 

  81. Kwong DL, Nicholls J, Wei WI, et al. The time course of histologic remission after treatment of patients with nasopharyngeal carcinoma. Cancer. 1999;85:1446–53.

    Google Scholar 

  82. Kwong DL, Wei WI, Cheng AC, et al. Long term results of radioactive gold grain implantation for the treatment of persistent and recurrent nasopharyngeal carcinoma. Cancer. 2001;91:1105–13.

    PubMed  CAS  Google Scholar 

  83. Law SC, Lam WK, Ng MF, et al. Reirradiation of nasopharyngeal carcinoma with intracavitary mold brachytherapy: an effective means of local salvage. Int J Radiat Oncol Biol Phys. 2002;54:1095–13.

    PubMed  Google Scholar 

  84. Yau TK, Sze WM, Lee WM, et al. Effectiveness of brachytherapy and fractionated stereotactic radiotherapy boost for persistent nasopharyngeal carcinoma. Head Neck. 2004;26:1024–30.

    PubMed  Google Scholar 

  85. Leung TW, Tung SY, Sze WK, et al. Salvage brachytherapy for patients with locally persistent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2000;47:405–12.

    PubMed  CAS  Google Scholar 

  86. Zheng XK, Chen LH, Chen YQ, et al. Three-dimensional conformal radiotherapy versus intracavitary brachytherapy for salvage treatment of locally persistent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2004;60:165–70.

    PubMed  Google Scholar 

  87. Wu SX, Chua DT, Deng ML, et al. Outcome of fractionated stereotactic radiotherapy for 90 patients with locally persistent and recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;69:761–9.

    PubMed  Google Scholar 

  88. Cmelak AJ, Cox RS, Adler JR, et al. Radiosurgery for skull base malignancies and nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1997;37:997–1003.

    PubMed  CAS  Google Scholar 

  89. Chua DT, Sham JS, Hung KN, et al. Salvage treatment for persistent and recurrent T1-2 nasopharyngeal carcinoma by stereotactic radiosurgery. Head Neck. 2001;23:791–8.

    PubMed  CAS  Google Scholar 

  90. Lee AW, Law SC, Foo W, et al. Retrospective analysis of patients with nasopharyngeal carcinoma treated during 1976-1985: survival after local recurrence. Int J Radiat Oncol Biol Phys. 1993;26:773–82.

    PubMed  CAS  Google Scholar 

  91. Yu KH, Leung SF, Tung SY, et al. Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Head Neck. 2005;27:397–405.

    PubMed  Google Scholar 

  92. Wang CC. Re-irradiation of recurrent nasopharyngeal carcinoma-treatment techniques and results. Int J Radiat Oncol Biol Phys. 1987;13:953–6.

    PubMed  CAS  Google Scholar 

  93. Pryzant RM, Wendt CD, Delclos L, et al. Re-treatment of nasopharyngeal carcinoma in 53 patients. Int J Radiat Oncol Biol Phys. 1992;22:941–7.

    PubMed  CAS  Google Scholar 

  94. Lee AW, Foo W, Law SC, et al. Reirradiation for recurrent nasopharyngeal carcinoma: factors affecting the therapeutic ratio and ways for improvement. Int J Radiat Oncol Biol Phys. 1997;38:43–52.

    PubMed  CAS  Google Scholar 

  95. Lee AW, Foo W, Law SC, et al. Total biological effect on late reactive tissues following reirradiation for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:865–72.

    PubMed  CAS  Google Scholar 

  96. Leung TW, Tung SY, Sze WK, et al. Salvage radiation therapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2000;48:1331–8.

    PubMed  CAS  Google Scholar 

  97. Chen HJ, Leung SW, et al. Linear accelerator based radiosurgery as a salvage treatment for skull base and intracranial invasion of recurrent nasopharyngeal carcinomas. Am J Clin Oncol. 2001;24:255–8.

    PubMed  CAS  Google Scholar 

  98. Chua DT, Sham JS, Hung KN, et al. Stereotactic radiosurgery as a salvage treatment for locally persistent and recurrent nasopharyngeal carcinoma. Head Neck. 1999;21:620–6.

    PubMed  CAS  Google Scholar 

  99. Pai PC, Chuang CC, Wei KC, et al. Stereotactic radiosurgery for locally recurrent nasopharyngeal carcinoma. Head Neck. 2002;24:748–53.

    PubMed  Google Scholar 

  100. Leung TW, Wong VY. Tung SY (2009) Stereotactic radiotherapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2009;75:734–41.

    PubMed  Google Scholar 

  101. Chua DT, Wei WI, Sham JS, et al. Stereotactic radiosurgery versus gold grain implantation in salvaging local failures of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;69:469–74.

    PubMed  Google Scholar 

  102. Chang JT, See LC, Liao CT, et al. Locally recurrent nasopharyngeal carcinoma. Radiother Oncol. 2000;54:135–42.

    PubMed  CAS  Google Scholar 

  103. Xiao J, Xu G, Miao Y. Fractionated stereotactic radiosurgery for 50 patients with recurrent or residual nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2001;51:164–70.

    PubMed  CAS  Google Scholar 

  104. Zheng XK, Ma J, Chen LH, et al. Dosimetric and clinical results of three-dimensional conformal radiotherapy for locally recurrent nasopharyngeal carcinoma. Radiother Oncol. 2005;75:197–203.

    PubMed  Google Scholar 

  105. Lu TX, Mai WY, Teh BS, et al. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2004;58:682–7.

    PubMed  Google Scholar 

  106. Chua DT, Sham JS, Leung LH, et al. Re-irradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy. Radiother Oncol. 2005;77:290–4.

    PubMed  Google Scholar 

  107. Chua DT, Sham JS, Au GK. Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma. Am J Clin Oncol. 2005;28:464–71.

    PubMed  CAS  Google Scholar 

  108. Poon D, Yap SP, Wong ZW, et al. Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2004;59:1312–8.

    PubMed  Google Scholar 

  109. Wei WI, Lam KH, Ho CM, et al. Efficacy of radical neck dissection for the control of cervical metastasis after radiotherapy for nasopharyngeal carcinoma. Am J Surg. 1990;160:439–42.

    PubMed  CAS  Google Scholar 

  110. Wei WI, Ho CM, Wong MP, et al. Pathological basis of surgery in the management of postradiotherapy cervical metastasis in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1992;118:923–9.

    PubMed  CAS  Google Scholar 

  111. Wei WI, Ho WK, Cheng AC, et al. Management of extensive cervical nodal metastasis in nasopharyngeal carcinoma after radiotherapy: a clinicopathological study. Arch Otolaryngol Head Neck Surg. 2001;127:1457–62.

    PubMed  CAS  Google Scholar 

  112. Fisch U. The infratemporal fossa approach for nasopharyngeal tumors. Laryngoscope. 1983;93:36–44.

    PubMed  CAS  Google Scholar 

  113. Fee Jr WE, Roberson Jr JB, Goffinet DR. Long-term survival after surgical resection for recurrent nasopharyngeal cancer after radiotherapy failure. Arch Otolaryngol Head Neck Surg. 1991;117:1233–6.

    PubMed  Google Scholar 

  114. Wei WI, Lam KH, Sham JS. New approach to the nasopharynx: the maxillary swing approach. Head Neck. 1991;13:200–7.

    PubMed  CAS  Google Scholar 

  115. Morton RP, Liavaag PG, Mclean M, et al. Transcervico-mandibulo-palatal approach for surgical salvage of recurrent nasopharyngeal cancer. Head Neck. 1996;18:352–8.

    PubMed  CAS  Google Scholar 

  116. Ng RW, Wei WI. Elimination of palatal fistula after the maxillary swing procedure. Head Neck. 2005;27:608–12.

    PubMed  Google Scholar 

  117. Ng RW, Wei WI. Quality of life of patients with recurrent nasopharyngeal carcinoma treated with nasopharyngectomy using the maxillary swing approach. Arch Otolaryngol Head Neck Surg. 2006;132:309–16.

    PubMed  Google Scholar 

  118. Fee Jr WE, Moir MS, Choi EC, et al. Nasopharyngectomy for recurrent nasopharyngeal cancer: a 2- to 17-year follow-up. Arch Otolaryngol Head Neck Surg. 2002;128:280–4.

    PubMed  Google Scholar 

  119. Wei WI. Nasopharyngeal cancer: current status of management. Arch Otolaryngol Head Neck Surg. 2001;127:766–9.

    PubMed  CAS  Google Scholar 

  120. Toh CK, Heng D, Ong YK, et al. Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma. Br J Cancer. 2005;92:1382–7.

    PubMed  Google Scholar 

  121. Hui EP, Leung SF, Au JS, et al. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer. 2004;101:300–6.

    PubMed  Google Scholar 

  122. Au E, Ang PT. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 1994;94:87–9.

    Google Scholar 

  123. Su WC, Chen TY, Kao RH, et al. Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan. Oncology. 1993;50:205–8.

    PubMed  CAS  Google Scholar 

  124. Siu LL, Czaykowski PM, Tannock IF. Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J Clin Oncol. 1998;16:2514–21.

    PubMed  CAS  Google Scholar 

  125. Hasbini A, Mahjoubi R, Fandi A, et al. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann Oncol. 1999;10:421–5.

    PubMed  CAS  Google Scholar 

  126. Taamma A, Fandi A, Azli N, et al. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer. 1999;86:1101–8.

    PubMed  CAS  Google Scholar 

  127. Chua DT, Sham JS, Au GK. A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2005;41:589–95.

    PubMed  CAS  Google Scholar 

  128. Li YH, Wang FH, Jiang WQ, et al. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2008;62:539–44.

    PubMed  CAS  Google Scholar 

  129. Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002;13:1252–8.

    PubMed  CAS  Google Scholar 

  130. McCarthy JS, Tannock IF, Degendorfer P, et al. A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol. 2002;38:686–90.

    PubMed  CAS  Google Scholar 

  131. Leong SS, Wee J, Rajan S, et al. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer. 2008;113:1332–7.

    PubMed  CAS  Google Scholar 

  132. Chua DT, Nicholls JM, Sham JS, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:11–20.

    PubMed  CAS  Google Scholar 

  133. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005;23:3568–76.

    PubMed  CAS  Google Scholar 

  134. Chua DT, Wei WI, Wong MP, et al. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck. 2008;30:863–7.

    PubMed  Google Scholar 

  135. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007;25:3766–73.

    PubMed  CAS  Google Scholar 

  136. Lee AW, Law SC, Ng SH, et al. Retrospective analysis of nasopharyngeal carcinoma treated during 1976–1985: late complications following megavoltage irradiation. Br J Radiol. 1992;65:918–28.

    PubMed  CAS  Google Scholar 

  137. Lee AW, Perez CA, Law CK et al. Nasopharynx. In: Halperin EC, Perez CA, Brady LW, editors. Principles and practice of radiation oncology, 5th edn. Philadelphia: Lippincott Williams & Wilkins; 2008b. p. 820–857

    Google Scholar 

  138. Lee AW, Ng WT, Hung WM, et al. Major Late toxicities following conformal radiotherapy for Nasopharyngeal Carcinoma – patient and treatment related risk factors. Int J Radiat Oncol Biol Phys. 2009;73:1121–8.

    PubMed  Google Scholar 

  139. Cheng KM, Chan CM, Cheung YL, et al. Endovascular treatment of radiation-induced petrous internal carotid artery aneurysm ­presenting with acute haemorrhage. A report of two cases. Acta Neurochir (Wien). 2001;143:351–6.

    CAS  Google Scholar 

  140. Kwong DL, Sham JS, Leung LH, et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;64:374–81.

    PubMed  Google Scholar 

  141. Cheng SW, Ting AC, Lam LK, et al. Carotid stenosis after radiotherapy for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2000;126:517–21.

    PubMed  CAS  Google Scholar 

  142. Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2004;60:1440–50.

    PubMed  Google Scholar 

  143. Bucci M, Xia P, Lee N, et al. Intensity modulated radiation therapy for carcinoma of the nasopharynx: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2004;60:S317–318.

    Google Scholar 

  144. Cheng KM, Chan CM, Fu YT, et al. Brain abscess formation in radiation necrosis of the temporal lobe following radiation therapy for nasopharyngeal carcinoma. Acta Neurochir (Wien). 2000;142:435–41.

    CAS  Google Scholar 

  145. Cheng KM, Chan CM, Fu YT, et al. Acute hemorrhage in late radiation necrosis of the temporal lobe: report of five cases and review of the literature. J Neurooncol. 2001;51:143–50.

    PubMed  CAS  Google Scholar 

  146. Young YH, Lou PJ. Post-irradiation sudden deafness. J Laryngol Otol. 1999;113:815–7.

    PubMed  CAS  Google Scholar 

  147. Chen CY, Young YH, Hsu WC, et al. Failure of grommet insertion in post-irradiation otitis media with effusion. Ann Otol Rhinol Laryngol. 2001;110:746–8.

    PubMed  CAS  Google Scholar 

  148. Cheng SJ, Lee JJ, Ting LL, et al. A clinical staging system and treatment guidelines for maxillary osteoradionecrosis in irradiated nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2006;64:90–7.

    PubMed  Google Scholar 

  149. Dickens P, Wei WI, Sham JS. Osteosarcoma of the maxilla in Hong Kong Chinese postirradiation for nasopharyngeal carcinoma. A report of four cases. Cancer. 1990;66:1924–6.

    PubMed  CAS  Google Scholar 

  150. King AD, Ahuja AT, Teo P, et al. Radiation induced sarcomas of the head and neck following radiotherapy for nasopharyngeal carcinoma. Clin Radiol. 2000;55:684–9.

    PubMed  CAS  Google Scholar 

  151. Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5,037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;23:261–70.

    PubMed  CAS  Google Scholar 

  152. Lee AW, Sze WM, Au SK, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005;61:1107–16.

    PubMed  Google Scholar 

  153. Pan JJ, Zhang SW, Chen CB, et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27:799–804.

    PubMed  Google Scholar 

  154. Kwong DL, Pow EH, Sham JS, et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer. 2004;101:1584–93.

    PubMed  Google Scholar 

  155. Lin S, Pan J, Han L, et al. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: Report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys. 2009;75:1071–78.

    PubMed  Google Scholar 

  156. Tham IW, Hee SW, Yeo RM, et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy – The National Cancer Centre Singapore experience. Int J Radiat Oncol Biol Phys. 2009;75:1481–86.

    PubMed  Google Scholar 

  157. Oh JL, Vokes EE, Kies MS, et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol. 2003;14:564–9.

    PubMed  CAS  Google Scholar 

  158. Wang CC, Chang JY, Liu TW, et al. Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma. Head Neck. 2006;28:74–80.

    PubMed  Google Scholar 

  159. Al-Amro A, Al-Rajhi N, Khafaga Y, et al. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2005;62:508–13.

    PubMed  Google Scholar 

  160. Johnson FM, Garden AS, Palmer JL, et al. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost ­chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2005;63:717–24.

    PubMed  CAS  Google Scholar 

  161. Yeo W, Leung TW, Chan AT, et al. A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer. 1998;34:2027–31.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong, China

    Anne W. M. Lee

Authors
  1. Anne W. M. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wai-Tong Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tsz-Kok Yau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen C. K. Law
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. William I. Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne W. M. Lee .

Editor information

Editors and Affiliations

  1. , Dept of Radio-Oncology, Genolier Swiss Medical Network, 4 Route du Muids, Genolier, CH-1272, Switzerland

    Jacques Bernier

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Lee, A.W.M., Ng, WT., Yau, TK., Law, S.C.K., Wei, W.I. (2011). Management of Nasopharyngeal Carcinoma. In: Bernier, J. (eds) Head and Neck Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9464-6_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9464-6_28

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-9463-9

  • Online ISBN: 978-1-4419-9464-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation